Case Studies

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Merkel Cell Carcinoma: Introduction

Case: Ron

MCC: Clinical Presentation

Ron: PET Scan and Surgery

Ron: 1 Month Post Surgery

Ron: Initiation of Immunotherapy

Ron: Neurologic AEs

Immune-Mediated AEs Associated With Checkpoint Inhibitors

Ron: Follow-Up Clinical Presentation

Case: Phillipe

Phillipe: Regional Lymph Node Relapse

Phillipe: Metastatic Disease

Reported Recurrence Rates for MCC

Phillipe: Initiation of Chemotherapy

CT Scans Prior to and Following Chemotherapy

Relapse and Retreatment

Enrollment in Clinical Trial: Baseline CT Scan

First Evaluation: CT Scan

Comparative PET Scans

PET Scan >1 Year After Discontinuing Avelumab

Unanswered Questions Regarding the Management of MCC

Immune Checkpoint Inhibitors: Mechanism of Action

Pembrolizumab: Key Study Highlights

Avelumab: Key Study Highlights and Updates

Patient Selection: Weighing the Risks and Benefits

Concluding Remarks and Future Directions

Abbreviations